Literature DB >> 23375852

Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.

Nosratola D Vaziri1.   

Abstract

Although judicious use of intravenous iron preparations is an indispensable part of anemia treatment in hemodialysis patients, their excessive and indiscriminate use can have insidious but serious adverse consequences. With recent implementation of the bundling reimbursement policy, use of intravenous iron preparations in the hemodialysis population has markedly increased. Excessive use of these agents potentially can exacerbate oxidative stress, inflammation, endothelial dysfunction, cardiovascular disease, and immune deficiency and potentially increases the risk of microbial infections in this population. Most of these adverse effects are mediated by iron-catalyzed generation of reactive oxygen species and the resultant cell injury and dysfunction. This review is intended to provide an overview of the nature and mechanisms of the adverse effects of iron overload and call for the judicious use of these vitally important products.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375852     DOI: 10.1053/j.ajkd.2012.10.027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  38 in total

1.  Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

Authors:  Keitaro Yokoyama; Hideki Hirakata; Takashi Akiba; Masafumi Fukagawa; Masaaki Nakayama; Kenichi Sawada; Yuji Kumagai; Geoffrey A Block
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 2.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Ferric pyrophosphate: good things come to those who wait?

Authors:  Lisa H Fell; Danilo Fliser; Gunnar H Heine
Journal:  Nephrol Dial Transplant       Date:  2015-07-21       Impact factor: 5.992

4.  Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.

Authors:  Wajeh Y Qunibi
Journal:  J Am Soc Nephrol       Date:  2015-03-03       Impact factor: 10.121

Review 5.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 6.  Safety of intravenous iron formulations: facts and folklore.

Authors:  Michael Auerbach; Iain C Macdougall
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

Review 7.  Iron in kidney and heart failure: from theory to practice.

Authors:  Aslihan Yerlikaya; Mustafa C Bulbul; Baris Afsar; Tuncay Dagel; Gamze Aslan; Luminita Voroneanu; Dimitire Siriopol; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2017-09-22       Impact factor: 2.370

Review 8.  The Gut as a Source of Inflammation in Chronic Kidney Disease.

Authors:  Wei Ling Lau; Kamyar Kalantar-Zadeh; Nosratola D Vaziri
Journal:  Nephron       Date:  2015-05-09       Impact factor: 2.847

9.  Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients.

Authors:  Xiaojuan Li; Stephen R Cole; Abhijit V Kshirsagar; Jason P Fine; Til Stürmer; M Alan Brookhart
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-15       Impact factor: 8.237

10.  Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study.

Authors:  Eyal Ben-Assa; Yacov Shacham; Moshe Shashar; Eran Leshem-Rubinow; Amir Gal-Oz; Idit F Schwartz; Doron Schwartz; Donald S Silverberg; Gil Chernin
Journal:  Cardiorenal Med       Date:  2015-07-04       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.